STOCK TITAN

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

10x Genomics (Nasdaq: TXG) has launched Xenium Protein, an innovative addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell and tissue section in a single automated run. This breakthrough represents the first fully integrated spatial multiomic workflow for the Xenium platform.

The new product features ready-to-use protein subpanels that work alongside RNA panels, including dozens of proteins involved in cell growth, signaling, and immune response. The technology streamlines research workflows by eliminating the need for separate technologies or sample sections, particularly beneficial for studying cancer, immunology, and complex diseases.

Early adoption by companies like Sanofi demonstrates the platform's value in providing comprehensive tissue architecture analysis and cell-cell interaction insights without complex data co-registration requirements.

Loading...
Loading translation...

Positive

  • First fully integrated spatial multiomic workflow enabling simultaneous RNA and protein detection
  • Streamlines research process by eliminating need for multiple technologies and complex data integration
  • Ready-to-use protein subpanels work seamlessly with existing RNA panels
  • Early adoption by major pharmaceutical companies like Sanofi

Negative

  • None.

News Market Reaction

-0.37%
1 alert
-0.37% News Effect

On the day this news was published, TXG declined 0.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology

PLEASANTON, Calif., Aug. 19, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Xenium Protein, a powerful new addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell, on the same tissue section, all in a single automated run. As the first fully integrated spatial multiomic workflow for the Xenium platform from 10x Genomics, Xenium Protein empowers researchers to generate deeper biological insights with high confidence and without the need to stitch together data from multiple technologies.

"Scientists can now analyze RNA and protein together, streamlining workflows, removing the need for complex data integration and unlocking more precise insights," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "Integrated multiomic analysis is essential to advancing our understanding of complex diseases and accelerating therapeutic discovery."

Xenium Protein expands the Xenium platform with ready-to-use protein subpanels that work seamlessly alongside RNA panels, all on the same slide. These initial subpanels include dozens of well-characterized proteins involved in cell growth, signaling and immune response – making them valuable for studying cancer, immunology and other complex disease areas.

By reducing the need for separate workflows, technologies or sample sections, Xenium Protein simplifies experimental design and shortens time to results. With both RNA and protein data captured in a single run, researchers can move more quickly from experiment to insight – accelerating the pace of valuable discoveries possible through multiomic analysis.

Early access customers are leveraging Xenium Protein from early discovery through translational research and large-scale atlasing efforts.

"Integrating RNA and protein analysis within the same Xenium workflow enables a comprehensive view of tissue architecture and cell-cell interactions in a single experiment," said Dr. Julien Tessier, Principal Scientist, Sanofi. "This integrated multiomics approach removes the reliance on data co-registration – which is often complex and can introduce uncertainty – while delivering critical insights into target and biomarker expression that RNA alone often fails to capture."

Xenium Protein is now available globally.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protein-analysis-302532774.html

SOURCE 10x Genomics, Inc.

FAQ

What is the new Xenium Protein product launched by 10x Genomics (TXG)?

Xenium Protein is a new addition to the Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell and tissue section in a single automated run, representing the first fully integrated spatial multiomic workflow from 10x Genomics.

How does Xenium Protein benefit researchers compared to existing methods?

Xenium Protein streamlines workflows by eliminating the need for separate technologies and complex data integration, allowing researchers to analyze RNA and protein together in a single run, which speeds up the time from experiment to insight.

What applications is the TXG Xenium Protein platform designed for?

The platform is designed for studying cancer, immunology, and other complex diseases through its protein subpanels that focus on cell growth, signaling, and immune response proteins.

When will Xenium Protein be available to researchers?

Xenium Protein is now available globally for researchers to use in their studies.

What are the key features of 10x Genomics' Xenium Protein platform?

Key features include ready-to-use protein subpanels that work alongside RNA panels, integrated multiomic analysis capabilities, and the ability to analyze both RNA and protein in the same cell and tissue section in a single automated run.
10X Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Latest SEC Filings

TXG Stock Data

2.85B
114.31M
1.86%
104.6%
11.03%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON